Successful treatment of disseminated granuloma annulare with adalimumab.
A 61-year-old female with a 4-year history of disseminated granuloma annulare was successfully treated with the antitumor necrosis factor (TNF)-alpha antibody, adalimumab. The patient had failed high potency topical glucocorticoids, hydroxychloroquine, and narrow-band ultraviolet light (UV)-B phototherapy. Anti-TNF-alpha therapy may be a therapeutic option in patients with disseminated granuloma annulare poorly controlled with conventional medications.
Rosmarin
David
D
Tufts Medical Center, Tufts University School of Medicine, Department of Dermatology, Boston, MA, USA.
LaRaia
Anne
A
Schlauder
Scott
S
Gottlieb
Alice B
AB
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D005260:Female; D016460:Granuloma Annulare / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006644:Histiocytes / Q000473:pathology / Q000648:ultrastructure; D006801:Humans; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab